¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"complement activating enzymes"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
¿µ¹® complement ÇÑ±Û º¸Ã¼
¼³¸í   
  Ç×ü¿Í ¹ÝÀÀÇÏ¿© Ç×ü¿Í °áÇյȠ¼¼Æ÷ÀÇ ÆÄ±«¸¦ ÀÏÀ¸Å°´Â ´Ü¹éÁúÀ» ¸»ÇÑ´Ù. Ç×ü°¡ Ç×ü¿Í °áÇÕÇÑ ¼¼Æ÷¸¦ ÆÄ±«Çϴ ¹æ¹ý¿¡´Â ¿©·¯ °¡Áö°¡ Àִµ¥ ±× ÁßÀÇ Çϳª·Î Ç×ü¿Í °áÇÕÇÑ ¼¼Æ÷ÀǠǥ¸éÀ» ºÎºÐÀûÀ¸·Î ¼Õ»ó½ÃÄÑ ±× ¼¼Æ÷¸¦ ÆÄ±«Çϴ ¿ªÇÒÀ» Çϴ °ÍÀÌ ÀÌ º¸Ã¼ÀÌ´Ù. º¸Ã¼´Â 20°¡ÁöÀÇ ´Ü¹éÁú·Î ±¸¼ºµÇ¾î Àִµ¥ ¾àÀڷΠC·Î Ç¥½ÃÇϸ砰¢ Á¾·ù¸¦ ³ªÅ¸³¾ °æ¿ì¿¡´Â C¿·¿¡ ¼ýÀÚ¸¦ ½á¼­ Ç¥½ÃÇÑ´Ù.
¿µ¹® complement fixation reaction ÇÑ±Û º¸Ã¼°áÇÕ ¹ÝÀÀ, µµ¿òü°áÇÕ¹ÝÀÀ
¼³¸í   
  Ç×ü¿ÍÀÇ ¹ÝÀÀ¿¡ À־ º¸Ã¼¿Í °áÇÕÇϴ Ç×ü¸¦ °Ë»çÇϴ ¹æ¹ýÀ¸·Î, ÀÌ ¹ÝÀÀÀº ÃÖÃÊ¿¡ ±âÁöÇ׿ø, ÇǰËÇ÷û ¹× º¸Ã¼¸¦ È¥ÇÕÇÑ´Ù. Á¦2´Ü°è¿¡¼­´Â ÀûÇ÷±¸¿Í À̰Ϳ¡ ´ëÀÀÇϴ ¿ëÇ÷¼ÒÀǠȥÇÕ¾×À» °¡ÇÑ´Ù. º» ¹ÝÀÀÈÄ ¿ëÇ÷ÀÌ ÀϾÁö ¾ÊÀ¸¸é º»Ã¼´Â Ç׿øÇ×ü°áÇÕ¹°¿¡ °áÇÕÇÑ °ÍÀÌ µÇ¾î ¾ç¼ºÀÌ µÇÁö¸¸, ¿ëÇ÷ÀÌ ÀϾ °æ¿ì º¸Ã¼´Â °áÇÕÇÏÁö ¾Ê¾Æ ¼ÒºñµÇÁö ¾Ê±â ¶§¹®¿¡ À½¼ºÀÌ µÈ´Ù. º» ¹ÝÀÀÀº ±âÁöÇ÷ûÀ» ½á¼­ Ç׿ø°ËÃâ¿¡ ÀÀ¿ëÇÒ ¼ö ÀÖÀ¸¸ç, ¸¶ÀÌÄÚÇö󽺸¶, ¸®ÄÉí, Å¬¶ó¹Ìµð¾Æ, ¹ÙÀÌ·¯½º, ¸Åµ¶ µîÀÇ Áø´Ü¿¡ ¾²ÀδÙ.
  
  
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • conglutinogen activating factor
    ±³Âø¿øÈ°¼ºÀÎÀÚ
  • lymphocyte activating factor
    ¸²ÇÁ±¸È°¼ºÀÎÀÚ
  • lymphocyte-activating determinant
    ¸²ÇÁ±¸È°¼º°áÁ¤ÀÎÀÚ
  • macrophage-activating factor
    Å«Æ÷½Ä¼¼Æ÷Ȱ¼ºÀÎÀÚ, ´ë½Ä¼¼Æ÷Ȱ¼ºÀÎÀÚ
  • platelet activating factor
    Ç÷¼ÒÆÇȰ¼ºÀÎÀÚ
  • alternative complement pathway
    ´ëüº¸Ã¼°æ·Î
  • classic complement pathway
    ÀüÇüÀûº¸Ã¼°æ·Î
  • complement
    º¸Ã¼, µµ¿òü
  • complement activation
    º¸Ã¼È°¼ºÈ­, µµ¿òüȰ¼ºÈ­
  • complement cascade
    º¸Ã¼¿¬¼â¹ÝÀÀ, µµ¿òü¿¬¼â¹ÝÀÀ
  • complement component
    º¸Ã¼¼ººÐ, µµ¿òü¼ººÐ
  • complement fixation
    º¸Ã¼°áÇÕ
  • complement fixation inhibition test
    º¸Ã¼°áÇÕ¾ïÁ¦°Ë»ç
  • complement fixation reaction
    º¸Ã¼°áÇÕ¹ÝÀÀ
  • complement fixation test
    º¸Ã¼°áÇÕ°Ë»ç
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • platelet activating factor
    Ç÷¼ÒÆÇȰ¼ºÀÎÀÚ
  • complement
    µµ¿òü, º¸Ã¼
  • complement cascade
    µµ¿òü¿¬¼â¹ÝÀÀ, º¸Ã¼¿¬¼â¹ÝÀÀ
  • complement fixation reaction
    µµ¿òü°áÇÕ¹ÝÀÀ, º¸Ã¼°áÇÕ¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • catabolite activating protein
    ÀÌÈ­»ê¹°È°¼ºÈ­´Ü¹é
  • conglutinogen activating factor
    ±³Âø¿øÈ°¼ºÀÎÀÚ
  • lymphocyte-activating determinant
    ¸²ÇÁ±¸È°¼º°áÁ¤±â
  • lymphocyte activating factor
    ¸²ÇÁ±¸È°¼ºÀÎÀÚ
  • macrophage-activating factor
    Å«Æ÷½Ä¼¼Æ÷Ȱ¼ºÀÎÀÚ
  • platelet activating factor
    Ç÷¼ÒÆÇȰ¼ºÀÎÀÚ
  • alternative complement pathway
    º¸Ã¼´ëü°æ·Î, µµ¿òü´ëü°æ·Î
  • complement activation
    µµ¿òüȰ¼º, º¸Ã¼È°¼º
  • complement-fixing antibody
    µµ¿òü°áÇÕÇ×ü, º¸Ã¼°áÇÕÇ×ü
  • complement
    µµ¿òü, º¸Ã¼
  • complement-induced
    (¢¡complement-mediated) µµ¿òü¸Å°³-
  • complement-mediated
    µµ¿òü¸Å°³-
  • classic complement pathway
    º¸Ã¼ÀüÇüÀû°æ·Î, µµ¿òüÀüÇüÀû°æ·Î
  • complement cascade
    º¸Ã¼¿¬¼âÁõÆø¹ÝÀÀ
  • complement component
    µµ¿òü¼ººÐ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Glycolytic enzymes
    ÇØ´çÈ¿¼Ò(ú°ÓØý£áÈ)
  • Intestinal mucosa, digestive enzymes
    Àå°üÁ¡¸·(íóηïÄØ¯), ¼ÒÈ­È¿¼Ò(á¼ûùý£áÈ)
  • hellp(hemolysis, elevated liver enzymes, low platelet),heliminths
    À±Ãæ(ëÌõù)
  • General anesthesia, reticular activating system and.
    Àü½Å¸¶Ãë(îïãóئö­), ¸Á»óüȰ¼ºÈ­°è(ØÑßÒô÷üÀàõûùͧ)
  • PAF =platelet activating factor
    Ç÷¼ÒÆÇȰ¼ºÀÎÀÚ.
  • PAF= platelet activating factor
    Ç÷¼ÒÆÇ Ȱ¼ºÀÎÀÚ.
  • T cell activating factor
    T¼¼Æ÷Ȱ¼ºÀÎÀÚ
  • guanosine triphosphate-activating protein
    »ïÀλ걸¾Æ³ë½Å Ȱ¼º´Ü¹éÁú
  • platelet activating factor
    Ç÷¼ÒÆÇ Ȱ¼º ÀÎÀÚ
  • platelet-activating factor (PAF)
    Ç÷¼ÒÆÇ Ȱ¼ºÈ­ÀÎÀÚ
  • platelet-activating factor (paf)
    Ç÷¼ÒÆÇȰ¼ºÈ­ÀÎÀÚ(úìá³÷ùüÀàõûùì×í­)
  • CR1 => complement receptor 1
    º¸Ã¼¼ö¿ëü 1
  • CR2 => complement receptor 2
    º¸Ã¼¼ö¿ëü 2
  • CR3 => complement receptor 3
    º¸Ã¼¼ö¿ëü 3
  • CR4 => complement receptor 4
    º¸Ã¼¼ö¿ëü 4
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • complement-induced = complement-mediated
    º¸Ã¼¸Å°³¼º
  • enzymes
    È¿¼Ò(ý£áÈ)
  • enzymes
    È¿¼Ò(ý£áÈ)
  • hellp(hemolysis, elevated liver enzymes, low platelet),heliminths
    À±Ãæ(ëÌõù)
  • iron porphyrin protein enzymes
    öÆ÷¸£ÇǸ°´Ü¹éÈ¿¼Ò(¡­Ó±ÛÜý£áÈ).
  • lysosomal enzymes
    ¸®¼Ò¼Ø¼º È¿¼Ò(¡­ ý£áÈ)
  • restriction enzymes
    Á¦ÇÑÈ¿¼Ò(ð¤ùÚý£áÈ)
  • catabolite activating protein
    ÀÌÈ­»ê¹° Ȱ¼ºÈ­´Ü¹éÁú
  • conglutinogen activating factor
    ±³Âø¿ø (conglutinogen, factor IÀÇ ¿¾¸»)
  • descending reticular activating system
    ÇÏÇ༺ ¸Á»óȰ¼º°è(ù»ú¼àõ ØÑßÒüÀàõͧ)
  • guanosine triphosphate-activating protein
    »ïÀλ걸¾Æ³ë½Å Ȱ¼º´Ü¹éÁú
  • lymphocyte activating factor
    ¸²ÇÁ±¸È°¼ºÀÎÀÚ
  • lymphocyte activating factor (LAF)
    ¸²ÇÁ±¸ Ȱ¼ºÈ­ÀÎÀÚ
  • lymphocyte-activating determinant
    ¸²ÇÁ±¸È°¼º °áÁ¤±â
  • macrophage activating factor (MAF)
    ´ë½Ä¼¼Æ÷ Ȱ¼ºÀÎÀÚ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • isofunctional enzymes
    µ¿±â´ÉÈ¿¼Ò(ÔÒÐüÒöý£áÈ)
  • activating enzyme
    "ºÎȰȿ¼Ò (Ý·üÀý£áÈ), Ȱ¼ºÈ­È¿¼Ò (üÀàõûùý£áÈ)"
  • acyl activating enzyme
    ¾Æ½ÇºÎȰȿ¼Ò (Ý·üÀý£áÈ)
  • amino acid activating enzyme
    ¾Æ¹Ì³ë»ê(ß«) Ȱ¼ºÈ­(üÀàõûù) È¿¼Ò(ý£áÈ)
  • fatty acid activating enzyme
    Áö¹æ»ê Ȱ¼ºÈ­ È¿¼Ò (ò·Û¸ß«üÀàõûùý£áÈ)
  • platelet-activating factor
    Ç÷¼ÒÆÇȰ¼º ÀÎÀÚ(úìá³÷ùüÀàõì×í­)
  • autoimmune complement fixation
    ÀÚ°¡¸é¿ª (í»Ê«Øóæ¹) º¸Ã¼°íÁ¤ (ÜÍô÷ͳïÒ)
  • complement
    º¸Ã¼(ÜÍô÷)
  • complement activation
    º¸Ã¼ Ȱ¼ºÈ­(ÜÍô÷üÀàõûù)
  • complement binding reaction
    º¸Ã¼°íÁ¤ ¹ÝÀÀ(ÜÍô÷ͳïÒÚãëë)
  • complement fixation
    º¸Ã¼°íÁ¤(ÜÍô÷ͳïÒ)
  • complement fixation inhibition test
    º¸Ã¼°íÁ¤ ÀúÇØ½ÃÇè(ÜÍô÷ͳïÒîÁúªãËúÐ)
  • complement fixation test
    º¸Ã¼°íÁ¤½ÃÇè(ÜÍô÷ͳïÒãËúÐ)
  • complement-fixing antibody
    º¸Ã¼°íÁ¤ Ç×ü(ÜÍô÷ͳïÒù÷ô÷)
  • indirect complement fixation test
    °£Á¢º¸Ã¼°íÁ¤½ÃÇè(ÊàïÈÜÍô÷ͳïÒãËúÐ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • complement
    º¸Ã¼, º¸Ãæ
  • complement fixation test
    º¸Ã¼°áÇÕ½ÃÇè
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
HELLP hemolysis, elevated liver enzymes, and low platelet count [syndrome]
KAF conglutinogen-activating factor; killer-assisting factor; kinase activating factor
LAF laminar air flow; Latin American female; leukocyte-activating factor; lymphocyte-activating factor
PAF paroxysmal atrial fibrillation; peroxisomal assembly factor; phosphodiesterase-activating factor; pl...
RAS rapid atrial stimulation; recurrent aphthous stomatitis; reflex activating stimulus; reliability, av...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CYPs Cytochrome P450 enzymes
HELLP Haemolysis, Elevated Liver Enzymes and Low Platelets
HELLP Hemolysis, Elevated Liver enzymes, and Low Platelet count
SBE Starch branching enzymes
UBCs Ubiquitin conjugating enzymes
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • macrophage activating factor
    ´ë½Ä ¼¼Æ÷ Ȱ¼º ÀÎÀÚ
  • platelet-activating factor
    Ç÷¼ÒÆÇ Ȱ¼º ÀÎÀÚ
  • reticular activating formation
    ¸Á»ó Ȱ¼º°è
  • complement activation
    º¸Ã¼ Ȱ¼º ÀÛ¿ë, º¸Ã¼ Ȱ¼ºÈ­
  • complement consumption test
    º¸Ã¼ ¼Òºñ ½ÃÇè
  • complement fixation inhibition test
    º¸Ã¼ °íÁ¤ ÀúÇØ ½ÃÇè
  • complement fixation test
    º¸Ã¼ °áÇÕ ½ÃÇè, º¸Ã¼ °áÇÕ °Ë»ç, º¸Ã¼ °íÁ¤ °Ë»ç
  • complement fixing antibody
    º¸Ã¼ °áÇÕ Ç×ü
  • complement splitting
    º¸Ã¼ ºÐÇØ
  • complement-mediated cytotoxicity
    º¸Ã¼ ¸Å°³¼º ¼¼Æ÷ µ¶¼º
  • inactivation of complement
    º¸Ã¼ ºñµ¿È­
  • serum complement titer
    Ç÷û º¸Ã¼ °¡ÃøÁ¤
    ¸ðµç º¸Ã¼ Ȱ¼ºÀÇ ÃÑÇÕÀ¸·Î¼­ ÃøÁ¤µÈ´Ù.
  • treponema pallidum complement fixation test
    Æ®·¹Æ÷³×¸¶ º¸Ã¼ °áÇÕ ½ÃÇè
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
complement activating enzymes <enzyme> Enzymes present in the complement system which activate one or more components in the system.
Registry number: EC 3.-
(12 Dec 1998)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
hydrolyzing enzymes <enzyme> Registry number: EC 3.
(12 Dec 1998)
splitting enzymes Enzyme's that, like aldolases, catalyze the conversion of a molecule into two smaller molecules without the addition or subtraction of any atoms.
(05 Mar 2000)
deamidizing enzymes <enzyme> Registry number: EC 3.5.
(12 Dec 1998)
deaminating enzymes Enzymes catalyzing simple hydrolysis of C-NH2 bonds of purines, pyrimidines, and pterins, usually named in terms of the substrate, e.g., guanine deaminases, adenosine deaminases, AMP deaminases, pterin deaminases and thus producing ammonia; not generally used for deamination of noncyclic amides. Deaminases are distinguished from ammonia-lyases (EC group 4.3.1) in that the latter produce an unsaturation at the point of NH3 removal.
Synonym: deaminating enzymes.
(05 Mar 2000)
debranching enzymes Enzyme's that bring about destruction of branches in glycogen; formerly considered to be one enzyme, now known to be a mixture of transferases (4-alpha-d-glucanotransferase) and hydrolases (amylo-1,6-glucosidase).
Synonym: debranching factors.
(05 Mar 2000)
digestive enzymes Enzymes that are utilised in the digestive system, enzymes that are hydrolases of macromolecules (e.g., amylases, proteinases).
(05 Mar 2000)
DNA restriction enzymes <enzyme> Enzymes that are part of the restriction-modification systems. They catalyze the endonucleolytic cleavage of DNA sequences which lack the species-specific methylation pattern in the host cell's DNA. Cleavage yields random or specific double-stranded fragments with terminal 5'-phosphates. The function of restriction enzymes is to destroy any foreign DNA that invades the host cell. most have been studied in bacterial systems, but a few have been found in eukaryotic organisms. They are also used as tools for the systematic dissection and mapping of chromosomes, in the determination of base sequences of dnas, and have made it possible to splice and recombine genes from one organism into the genome of another.
Registry number: EC 3.1.21
(12 Dec 1998)
DNA restriction-modification enzymes Systems consisting of two enzymes, a modification methylase and a restriction endonuclease. They are closely related in their specificity and protect the DNA of a given bacterial species. The methylase adds methyl groups to adenine or cytosine residues in the same target sequence that constitutes the restriction enzyme binding site. The methylation renders the target site resistant to restriction, thereby protecting DNA against cleavage.
(12 Dec 1998)
transferring enzymes <enzyme> Transferases are enzymes transferring a group, for example, the methyl group or a glycosyl group, from one compound (generally regarded as donor) to another compound (generally regarded as acceptor). The classification is based on the scheme "donor:acceptor group transferase".
Registry number: EC 2.
(12 Dec 1998)
enzymes, coenzymes, and enzyme inhibitors Proteins or RNA that act as biological catalysts, their cofactors, and inhibitors.
(12 Dec 1998)
enzymes, immobilised Enzymes which are immobilised on or in a variety of water-soluble or water-insoluble matrices with little or no loss of their catalytic activity. Since they can be reused continuously, immobilised enzymes have found wide application in the industrial, medical and research fields.
(12 Dec 1998)
acetyl-activating enzyme A ligase that catalyses the reaction of acetate and CoA and ATP to form AMP, pyrophosphate, and acetyl-CoA. A key step in the activation of acetate.
Synonym: acetate thiokinase, acetate-CoA ligase, acetyl-activating enzyme, acetyl-CoA synthetase.
(05 Mar 2000)
acyl-activating enzyme <enzyme> Fatty acid thiokinase (long-chain), a ligase forming acyl-CoA, AMP, and pyrophosphate from long-chain fatty acids, ATP, and coenzyme A. Activity is independent of phosphatidylcholine
Registry number: EC 6.2.1.3
Synonym: acyl-activating enzyme, dodecanoyl-CoA synthetase, fatty acid thiokinase (long chain), acid-coenzyme a ligase, fatty acid-CoA ligase, acyl-CoA synthetase, acyl-CoA ligase, coash ligase, ciprofibroyl-CoA synthetase, pristanoyl-CoA synthetase, palmityl CoA synthetase, palmitoyl CoA synthetase, palmitoyl CoA ligase, fatty acyl-CoA synthetase, very long chain fatty acid acyl-CoA synthetase, vlcfa acyl-CoA synthetase, nafenopin-CoA ligase, palmitoyl-CoA synthase, faa2 gene product, faa2p protein, vlacs enzyme
(26 Jun 1999)
amino acid activating enzyme <enzyme> Enzymes catalyzing the formation of a specific aminoacyl-tRNA from an amino acid and adenosine 5'-triphosphate with the concomitant formation of adenosine 5'-monophosphate and pyrophosphate.
Synonym: amino acid activating enzyme, aminoacyl-tRNA ligases.
(05 Mar 2000)
anionic neutrophil activating peptide <cytokine> A cytokine that activates neutrophils and attracts neutrophils and T-lymphocytes.
It is released by several cell types including monocytes, macrophages, T-lymphocytes, fibroblasts, endothelial cells, and keratinocytes by an inflammatory stimulus. Il-8 is a member of the beta-thromboglobulin superfamily and structurally related to platelet factor 4.
Acronym: IL-8
(12 Dec 1998)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 1 ÆäÀÌÁö: 1
  • Complement Activating Enzymes - »õâ Enzymes that activate one or more COMPLEMENT PROTEINS in the complement system leading to the formation of the COMPLEMENT MEMBRANE ATTACK COMPLEX, an important response in host defense. They are enzymes in the various COMPLEMENT ACTIVATION pathways.
    Synonyms : Activating Enzymes, Complement, Enzymes, Complement Activating
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • complement
    º¸ÃæÇÏ¿© ¿ÏÀüÇÏ°Ô ÇÏ´Â °Í
  • complement
    º¸ÃæÇÏ¿© ¿ÏÀüÇÏ°Ô ÇÏ´Â °Í;º¸¿Ï¹°;¿©¼ö;¿©°¢;¿©È£;º¸ÃæÀ½Á¤;(ÇÊ¿äÇÑ)Àü¼ö;Àü·®;½Â¹«¿ø Á¤¿ø;º¸ÃæÇÏ¿© ¿ÏÀüÄÉÇÏ´Ù;º¸¿Ï(º¸Ãæ)ÇÏ´Ù;...ÀÇ º¸¿ÏÀÌ µÇ´Ù
  • complement fixation
    º¸Ã¼ °áÇÕ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á